EnMed MicroAnalytics is an infant-health screening services provider created around the development of our proprietary EEvCarrier™ – the only screening solution that detects any levels of lead and other dangerous heavy metals accurately and easily [i.e., without a blood draw] in newborn babies, young children, and even pregnant women.
EnMed is a health screening provider of a diagnostic service/product for Covid-19 antibodies that is self-administered and is minimally invasive.
At Enmed Microanalytics, Our Mission Is:
- Toxic exposures to lead and other heavy metals contribute to tens of thousands of preventable cases of mental retardation nationwide. EnMed has developed a proprietary heavy metals analytical device and screening methodology that will permit simple and inexpensive lead and heavy metal screening of every pregnant woman, newborn, and older infant. This proprietary technology complies with currently used newborn metabolic screening programs that are routine and mandated in every state and most developed countries.
- We have also developed and market retail packets to test home and school water supplies, whether well or municipal supplied water. Every child has the right to be born and develop without being burdened with the adverse effects of toxic lead or heavy metal contamination.
- With the onset of the coronavirus pandemic, EnMed has focused its extensive experience with dried blood spot specimen collection by finger stick on filter paper cards for the screening of COVID-19 antibodies (IgG). This testing is critical to getting our country back to normal and EnMed is committed to that goal.
- We are also actively involved in the evaluation and development of additional population-based screening tests for a variety of disorders.